Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 USD | -0.86% | -0.86% | -21.02% |
Apr. 19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Financials (USD)
Sales 2022 | 25.9M | Sales 2023 | 42.81M | Capitalization | 17.99M |
---|---|---|---|---|---|
Net income 2022 | -33M | Net income 2023 | -24M | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M | Net cash position 2023 | 26.37M | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | 48 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.57% |
Latest transcript on Pieris Pharmaceuticals, Inc.
1 day | -2.77% | ||
1 week | -6.60% | ||
Current month | -20.85% | ||
1 month | -20.20% | ||
3 months | -9.32% | ||
6 months | -40.77% | ||
Current year | -20.33% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 70 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 11.5 | -0.86% | 3 739 |
24-04-25 | 11.6 | -2.77% | 28,528 |
24-04-24 | 11.93 | -0.58% | 40,170 |
24-04-23 | 12 | +2.67% | 115,544 |
24-04-22 | 11.69 | +0.76% | 23,548 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-20.33% | 14.35M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.76% | 22.02B | |
-17.84% | 20.9B | |
-9.23% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- PIRS Stock